[Evaluation of the "squamous cell carcinoma antigen" as marker of epidermoid cancer of the anal canal].
The authors studied the value of Squamous Cell Carcinoma Antigen (SCC) in squamous carcinoma of the anal canal in 66 patients. Assays were made at the time of diagnosis, before any treatment and during follow-up. A total of 353 assays were made. The positive threshold was selected at 2 ng/ml. At the time of diagnosis, sensitivity of the marker was 44 per cent and its specificity 92 per cent. In our series, pre-treatment SCC levels were not correlated with T by the Papillon classification, but were correlated with lymph node involvement (p less than 0.05). They had no prognostic value at the time of the initial diagnosis. During follow-up, at the time of recurrence, SCC levels were 20.3 +/- 43 ng/ml. This rise was significant (p less than 0.01), the sensitivity of the marker being 77 per cent. In patients who had a recurrence, the outcome was correlated with SCC levels and the latter were of prognostic value (p less than 0.01). In conclusion, SCC levels should form part of the clinical monitoring of patients with a squamous carcinoma of the anal canal.
Fontana
X
X
Service de Médecine Nucléaire, Centre Antoine-Lacassagne, Nice.
Lagrange
J L
JL
François
E
E
Bourry
J
J
Chauvel
P
P
Sordage
M
M
Lapalus
F
F
Namer
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood*; D001005:Anus Neoplasms / Q000097:blood* / Q000453:epidemiology / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000453:epidemiology / Q000473:pathology; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood; D009367:Neoplasm Staging / Q000379:methods; D011379:Prognosis; D012680:Sensitivity and Specificity; D015843:Serpins
D000951:Antigens, Neoplasm; D015843:Serpins; C051072:squamous cell carcinoma-related antigen
Evaluation du "Squamous Cell Carcinoma Antigen" comme marqueur du cancer epidermoïde du canal anal.